Literature DB >> 30870006

Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.

Jun-Jie Lei1, Hui-Qing Li1, Zhi-Huai Mo1, Ke-Jia Liu1, Ling-Juan Zhu1, Chun-Yi Li1, Wen-Li Chen2, Lei Zhang1.   

Abstract

The effective therapeutic approach of cerebral infarction is limited because of its underlying complexity. Recently, multiple long noncoding RNAs (lncRNAs) have been identified in the pathogenesis of cerebral infarction. Here, the current study aims to explore the interaction among lncRNA cyclin-dependent kinase inhibitor-2B-antisense RNA 1 (CDKN2B-AS1), transcription factor B-cell lymphoma/leukemia 11A (BCL11A), and MAPKK kinase kinase 1 (MAP4K1) and further investigate whether they affect cerebral infarction progression. The expression of CDKN2B-AS1, BCL11A, and MAP4K1 was altered in lymphocytes extracted from patients with cerebral infarction. In order to identify their roles in regulatory T (Treg) cells, the proliferation and apoptosis of the CD4+CD25+ Treg cells were examined, and levels of IL-4, IL-10, and TGF-β were determined. Also, the RNA crosstalk among CDKN2B-AS1, BCL11A, and MAP4K1 was validated. Finally, we established a rat model of middle cerebral arterial occlusion to evaluate the neurologic impairment and cerebral infarction volume. The results revealed that lymphocytes in patients with cerebral infarction presented with the up-regulated expression of CDKN2B-AS1. Moreover, BCL11A could specifically bind to CDKN2B-AS1 and MAP4K1 promoter so as to inhibit MAP4K1. Moreover, it was observed that down-regulated CDKN2B-AS1 inhibited CD4+CD25+ Treg-cell proliferation, reduced levels of IL-4, IL-10, and TGF-β and cerebral infarction volume, and elevated MAP4K1 expression. Collectively, our study provides evidence that CDKN2B-AS1 silencing could increase MAP4K1 expression to inhibit the CD4+CD25+ Treg-cell proliferation by reducing enrichment of transcription factor BCL11A, thereby protecting against cerebral infarction progression, highlighting a promising therapeutic strategy for treating cerebral infarction.-Lei, J.-J., Li, H.-Q., Mo, Z.-H., Liu, K.-J., Zhu, L.-J., Li, C.-Y., Chen, W.-L., Zhang, L. Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.

Entities:  

Keywords:  CD4CD25 T cell; gene silencing; proliferation

Mesh:

Substances:

Year:  2019        PMID: 30870006     DOI: 10.1096/fj.201802252R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

Review 1.  Long non-coding RNAs: the tentacles of chromatin remodeler complexes.

Authors:  Audrey Vincent; Isabelle Van Seuningen; Bernadette Neve; Nicolas Jonckheere
Journal:  Cell Mol Life Sci       Date:  2020-10-01       Impact factor: 9.261

2.  Long non-coding RNA lincRNA-erythroid prosurvival (EPS) alleviates cerebral ischemia/reperfusion injury by maintaining high-temperature requirement protein A1 (Htra1) stability through recruiting heterogeneous nuclear ribonucleoprotein L (HNRNPL).

Authors:  Haifeng Guo; Xia Guo; Shiting Jiang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  NCK1-AS1 promotes the progression of lung squamous cell carcinoma through transcriptionally upregulating NCK1 via interacting with MYC.

Authors:  Xia Zhou; Wuan Bao; Danhong Zhang; Yang Yang; Xianghui Du; Guoqin Qiu
Journal:  Cancer Biol Ther       Date:  2021-02-25       Impact factor: 4.742

4.  Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis.

Authors:  Jing Chang; Yanming Yu; Zhan Fang; Haiyan He; Dan Wang; Jian Teng; Lina Yang
Journal:  Diabetol Metab Syndr       Date:  2020-12-09       Impact factor: 3.320

5.  SPAG5-AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway.

Authors:  Jun Xu; Yujie Deng; Yi Wang; Xiaofang Sun; Shuqin Chen; Guoxiang Fu
Journal:  Cell Prolif       Date:  2020-01-19       Impact factor: 6.831

6.  LncRNA LL22NC03-N14H11.1 promoted hepatocellular carcinoma progression through activating MAPK pathway to induce mitochondrial fission.

Authors:  Tingzhuang Yi; Hongcheng Luo; Fengxue Qin; Qi Jiang; Shougao He; Tonghua Wang; Jianwei Su; Sien Song; Xiaoshan Qin; Yueqiu Qin; Xihan Zhou; Zansong Huang
Journal:  Cell Death Dis       Date:  2020-10-07       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.